Pharsight

Abilify Maintena Kit patents expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
ABILIFY MAINTENA KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5006528 OTSUKA PHARM CO LTD Carbostyril derivatives
Oct, 2014

(9 years ago)

US8993761 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(1 year, 8 months ago)

US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(1 year, 30 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5006528

(Pediatric)

OTSUKA PHARM CO LTD Carbostyril derivatives
Apr, 2015

(9 years ago)

US5006528 OTSUKA PHARM CO LTD Carbostyril derivatives
Apr, 2015

(9 years ago)

US9089567 OTSUKA PHARM CO LTD Method of treating cognitive impairments and schizophrenias
Jan, 2022

(2 years ago)

US8759351 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(9 months ago)

US8338428 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(9 months ago)

US7807680 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(4 months from now)

US8722679 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(4 months from now)

US8030313 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(4 months from now)

US8338427 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Mar, 2025

(9 months from now)

US11154553 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US11400087 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US11344547 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US10980803 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US10525057 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Mar, 2034

(9 years from now)

US11648347 OTSUKA PHARM CO LTD Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
Apr, 2034

(9 years from now)

Abilify Maintena Kit is owned by Otsuka Pharm Co Ltd.

Abilify Maintena Kit contains Aripiprazole.

Abilify Maintena Kit has a total of 18 drug patents out of which 7 drug patents have expired.

Expired drug patents of Abilify Maintena Kit are:

  • US5006528*PED
  • US5006528
  • US9089567
  • US8759351
  • US8338428
  • US5006528
  • US8993761

Abilify Maintena Kit was authorised for market use on 28 February, 2013.

Abilify Maintena Kit is available in for suspension, extended release;intramuscular dosage forms.

Abilify Maintena Kit can be used as treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia, maintenance monotherapy treatment of bipolar i disorder, maintenance monotherapy treatment of bipolar 1 disorder, treatment of schizophrenia, use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia, use of aripiprazole in extended release injectable suspension.

The generics of Abilify Maintena Kit are possible to be released after 06 April, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-746) Jul 27, 2020
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Tr...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents